BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 7738163)

  • 1. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
    Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
    J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding and cross-linking of recombinant mouse interferon-gamma to receptors in mouse leukemic L1210 cells; interferon-gamma internalization and receptor down-regulation.
    Wietzerbin J; Gaudelet C; Aguet M; Falcoff E
    J Immunol; 1986 Apr; 136(7):2451-5. PubMed ID: 2936825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.
    Hansen MB; Svenson M; Bendtzen K
    Clin Exp Immunol; 1992 Jun; 88(3):559-62. PubMed ID: 1606741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta.
    Yoshida R; Murray HW; Nathan CF
    J Exp Med; 1988 Mar; 167(3):1171-85. PubMed ID: 2965208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
    Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
    Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
    Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
    Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of an interferon-beta1a product.
    Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
    Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
    Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
    J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to equine interferon-alpha (IFN-alpha): new tools to neutralize IFN-activity and to detect secreted IFN-alpha.
    Wagner B; Hillegas JM; Flaminio MJ; Wattrang E
    Vet Immunol Immunopathol; 2008 Oct; 125(3-4):315-25. PubMed ID: 18586327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) omega 1: evidence that IFN-omega 1 is a component of human leukocyte IFN.
    Adolf GR
    Virology; 1990 Apr; 175(2):410-7. PubMed ID: 1691561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype.
    Krasagakis K; Garbe C; Krüger S; Orfanos CE
    J Invest Dermatol; 1991 Aug; 97(2):364-72. PubMed ID: 1712824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoassay for the quantitation of human leukocyte interferon.
    Berthold W; Merk W; Adolf GR
    Arzneimittelforschung; 1985; 35(1A):364-9. PubMed ID: 4039175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
    Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
    Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
    Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
    Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S; Flanagan P; Blackinton D; Wanebo H
    Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.